Targeted delivery of Protein Arginine Deiminase-4 inhibitors to limit arterial intimal NETosis and preserve endothelial integrity.

AIMS Recent evidence suggests that "vulnerable plaques," which have received intense attention as underlying mechanism of acute coronary syndromes over the decades, actually rarely rupture and cause clinical events. Superficial plaque erosion has emerged as a growing cause of residual thrombotic complications of atherosclerosis in an era of increased preventive measures including lipid lowering, anti-hypertensive therapy, and smoking cessation. The mechanisms of plaque erosion remain poorly understood, and we currently lack validated effective diagnostics or therapeutics for superficial erosion. Eroded plaques have a rich extracellular matrix, an intact fibrous cap, sparse lipid, and few mononuclear cells, but do harbor neutrophil extracellular traps (NETs). We recently reported that NETs amplify and propagate the endothelial damage at the site of arterial lesions that recapitulate superficial erosion in mice. We showed that genetic loss of protein arginine deiminase (PAD)-4 function inhibited NETosis and preserved endothelial integrity. The current study used systemic administration of targeted nanoparticles to deliver an agent that limits NETs formation to probe mechanisms of and demonstrate a novel therapeutic approach to plaque erosion that limits endothelial damage. METHODS AND RESULTS We developed Collagen IV-targeted nanoparticles (Col IV NP) to deliver PAD4 inhibitors selectively to regions of endothelial cell sloughing and collagen IV-rich basement membrane exposure. We assessed the binding capability of the targeting ligand in vitro and evaluated Col IV NP targeting to areas of denuded endothelium in vivo in a mouse preparation that recapitulates features of superficial erosion. Delivery of the PAD4 inhibitor GSK484 reduced NET accumulation at sites of intimal injury and preserved endothelial continuity. CONCLUSIONS NPs directed to Col IV show selective uptake and delivery of their payload to experimentally eroded regions, illustrating their translational potential. Our results further support the role of PAD4 and NETs in superficial erosion.

[1]  P. Libby,et al.  Roles of PAD4 and NETosis in Experimental Atherosclerosis and Arterial Injury: Implications for Superficial Erosion , 2018, Circulation research.

[2]  G. Pruijn,et al.  NETosis, complement, and coagulation: a triangular relationship , 2018, Cellular & Molecular Immunology.

[3]  J. Ärnlöv,et al.  Pharmacological targeting of peptidylarginine deiminase 4 prevents cancer-associated kidney injury in mice , 2017, Oncoimmunology.

[4]  O. Farokhzad,et al.  Targeted Nanotherapeutics Encapsulating Liver X Receptor Agonist GW3965 Enhance Antiatherogenic Effects without Adverse Effects on Hepatic Lipid Metabolism in Ldlr−/− Mice , 2017, Advanced healthcare materials.

[5]  Jonathan Rasmussen,et al.  Tumor Microenvironment-Responsive Multistaged Nanoplatform for Systemic RNAi and Cancer Therapy. , 2017, Nano letters.

[6]  P. Libby,et al.  Flow Perturbation Mediates Neutrophil Recruitment and Potentiates Endothelial Injury via TLR2 in MiceNovelty and Significance , 2017 .

[7]  Hang Lee,et al.  Effective anti-thrombotic therapy without stenting: intravascular optical coherence tomography-based management in plaque erosion (the EROSION study) , 2016, European heart journal.

[8]  Gerard Pasterkamp,et al.  Temporal shifts in clinical presentation and underlying mechanisms of atherosclerotic disease , 2017, Nature Reviews Cardiology.

[9]  Omid C Farokhzad,et al.  Ultra-pH-Responsive and Tumor-Penetrating Nanoplatform for Targeted siRNA Delivery with Robust Anti-Cancer Efficacy. , 2016, Angewandte Chemie.

[10]  Suresh Gadde,et al.  Targeted Interleukin-10 Nanotherapeutics Developed with a Microfluidic Chip Enhance Resolution of Inflammation in Advanced Atherosclerosis. , 2016, ACS nano.

[11]  P. Libby,et al.  Redundancy of IL-1 Isoform Signaling and Its Implications for Arterial Remodeling , 2016, PloS one.

[12]  P. Libby,et al.  Requiem for the 'vulnerable plaque'. , 2015, European heart journal.

[13]  O. Guenat,et al.  Primary Human Lung Pericytes Support and Stabilize In Vitro Perfusable Microvessels. , 2015, Tissue engineering. Part A.

[14]  O. Farokhzad,et al.  Targeted nanoparticles containing the proresolving peptide Ac2-26 protect against advanced atherosclerosis in hypercholesterolemic mice , 2015, Science Translational Medicine.

[15]  David M. Wilson,et al.  Inhibition of PAD4 activity is sufficient to disrupt mouse and human NET formation , 2015, Nature chemical biology.

[16]  O. Farokhzad,et al.  A Solvent-Free Thermosponge Nanoparticle Platform for Efficient Delivery of Labile Proteins , 2014, Nano letters.

[17]  P. Kubes,et al.  NETosis: how vital is it? , 2013, Blood.

[18]  Robert Langer,et al.  Development and in vivo efficacy of targeted polymeric inflammation-resolving nanoparticles , 2013, Proceedings of the National Academy of Sciences.

[19]  P. Thompson,et al.  Activation of PAD4 in NET formation , 2012, Front. Immun..

[20]  Akiko Maehara,et al.  A prospective natural-history study of coronary atherosclerosis. , 2011, The New England journal of medicine.

[21]  Robert Langer,et al.  Spatiotemporal controlled delivery of nanoparticles to injured vasculature , 2010, Proceedings of the National Academy of Sciences.

[22]  O. Tricot,et al.  Relation between endothelial cell apoptosis and blood flow direction in human atherosclerotic plaques. , 2000, Circulation.

[23]  P. Libby,et al.  Inflammatory Cytokines and Oxidized Low Density Lipoproteins Increase Endothelial Cell Expression of Membrane Type 1-Matrix Metalloproteinase* , 1999, The Journal of Biological Chemistry.

[24]  P. Libby,et al.  Inducible interleukin-1 gene expression in human vascular smooth muscle cells. , 1986, The Journal of clinical investigation.